Join
Live feed
·
INSIDERFilingvia Quantisnow
Spyre Therapeutics Inc. logo

Director Henderson Michael Thomas acquired 63,227 shares, increasing direct ownership by 60% to 168,606 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
SYRE· Spyre Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SYRE (Spyre Therapeutics Inc.) and more on Quantisnow.